DONGJIE SUN^1,2, CHI ZHANG^3,*

Oncology Research, Vol.31, No.5, pp. 753-767, 2023, DOI:10.32604/or.2023.029287 - 21 July 2023

Abstract Lung adenocarcinoma (LUAD) is the leading cause of cancer-related deaths, accounting for over a million deaths worldwide annually. Immunogenic cell death (ICD) elicits an adaptive immune response. However, the role of ICD-related long noncoding RNAs (lncRNAs) in LUAD is unknown. In this study, we investigated the characteristics of the tumor microenvironment in LUAD, the prognostic significance of ICD-related lncRNAs, and the half-maximal inhibitory concentration (IC50) of possible chemotherapeutic drugs. We sorted prognostic lncRNAs using univariate Cox regression and constructed a risk signature based on them. We then confirmed the model’s accuracy and generated a nomogram.… More > Graphic Abstract

Jian-lin Yang^*1, Ye Qin^*1, Liang Li^†, Chu-yu Cao^*, Qing Wang^*, Qian Li^*, Ya-feng Lv^*, Yanlin Wang^*

Oncology Research, Vol.23, No.1-2, pp. 79-86, 2015, DOI:10.3727/096504015X14478843952942

Abstract In the process of tumor cell apoptosis induced by specific regents, calreticulin (CRT) was transferred from endoplasmic reticulum (ER) onto the cell membrane. These tumor cells, when used as the cellular vaccine to immunize experimental animals, could initiate effective antitumor immunoresponse against homologous tumor cells. This is referred to as immunogenic cell death. Lidamycin (LDM) is an enediyne antibiotic, which has extremely potent cytotoxicity to cancer cells. In this study, the mouse melanoma B16-F1 cancer cells were used to investigate the ability of LDM in promoting immunogenic cell death. Our data showed that LDM could… More >